Turn Therapeutics invites public investment for expansion of flagship wound formula into eczema, toenail fungus
LOS ANGELES , May 23 /Businesswire/ - Turn Therapeutics launched its first public investment campaign today to fund clinical trials of its FDA-cleared antimicrobial ointment for two potential new drug indications: moderate to severe eczema and onychomycosis, or toenail fungus.